SCHEMBL3012190

SCHEMBL3012190

Cc1ccc(C)c(-c2csc(N3CCC(S(=O)(=O)c4ccccc4Br)CC3)n2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 3/20 0.55
SMN1; SMN2 Q16637 4/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
CTSS P25774 1/20 0.40
NFKB1 P19838 2/20 0.39
NFKB2 Q00653 2/20 0.39
RELA Q04206 2/20 0.39
KMT2A Q03164 2/20 0.39
MEN1 O00255 1/20 0.39
LMNA P02545 1/20 0.39
MAPK1 P28482 1/20 0.39
ALDH1A1 P00352 1/20 0.38
CYP1A2 P05177 1/20 0.38
POLB P06746 1/20 0.38
MAPT P10636 1/20 0.38
CYP2C9 P11712 1/20 0.38
HPGD P15428 1/20 0.38
CYP2C19 P33261 1/20 0.38
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3012566 0.90 SMN1; SMN2 (0.44) ARSMN1; SMN2NPC1RAB9ACTSS
SCHEMBL3002312 0.89 AR (0.55) ARSMN1; SMN2NPC1RAB9ACTSS
SCHEMBL3011660 0.87 CTSS (0.41) ARSMN1; SMN2NPC1RAB9ACTSS
SCHEMBL3007132 0.86 SMN1; SMN2 (0.55) ARSMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL3022490 0.86 AR (0.53) ARSMN1; SMN2NPC1RAB9ACTSS
SCHEMBL3013173 0.86 AR (0.53) ARSMN1; SMN2NPC1RAB9ACTSS
SCHEMBL3006509 0.86 SMN1; SMN2 (0.46) ARSMN1; SMN2NPC1RAB9ACTSS
SCHEMBL3019068 0.86 SMN1; SMN2 (0.46) SMN1; SMN2NPC1RAB9ACTSSKMT2A
SCHEMBL3013469 0.86 SMN1; SMN2 (0.42) ARSMN1; SMN2NPC1RAB9ACTSS
SCHEMBL3002420 0.85 KMT2A (0.45) ARSMN1; SMN2NPC1RAB9ACTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA AR 3801/4885SMN1; SMN2 1/4885NPC1 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.